Moneycontrol Pro Panorama | Will patent waiver increase vaccine production? The jury is out.

Unsurprisingly, the pharma industry is up in arms. It is afraid that this will set a bad precedent and kill innovation. Some in the US fear that new and protected technologies such as messenger RNA (the backbone of the Pfizer and Moderna jabs) will end up in the hands of rivals in China and Russia. Messenger RNA technology, in particular, is being tested to treat other diseases such as cancer and healthcare, and this move could put billions of dollars of future profit in jeopardy for these pharma companies.

Moreover, they claim that just waiving patents will not do any good because very few nations and companies have the know-how or expertise to produce vaccines, which are more complex than drugs. Essentially, they are saying that if you don’t have cooking chops, what will you do with the recipe?

The opposing side has some persuasive arguments, too. Nations have subsidised research and helped out pharma companies by placing huge advance orders – thus they are bound to share the technology. Writing in the Washington Post, Nobel laureate Joseph Stiglitz said the argument of developing nations not having the skill to manufacture COVID-19 vaccines “is self-serving and wrong”.

Ultimately, the fact is that unless global herd immunity is reached, the coronavirus might just hang about and keep mutating. Moreover, some of these mutants might be able to beat the vaccines and induce further waves of infections and lockdowns. The solution clearly is to increase vaccine production massively and quickly.

Will a patent waiver help that?

In theory, a TRIPS waiver means that any pharma company can make a version of the drug/vaccine without fear of getting sued.

But some say a patent waiver by itself won’t be enough. After all, Moderna had said last year that it won’t be enforcing its patents on the COVID jab. But as Doctors Without Borders pointed out, that is inadequate since know-how, technology, and other components of vaccine development and manufacturing can still be protected under IP rules.

“These components are also barriers for alternative manufacturers that want to make more affordable versions of Moderna’s vaccine and, if they remain in place, will likely keep vaccines out of the hands of people all over the world,” it said.

Then, there is the question of raw material supply. As the Financial Times has pointed out that vaccine production has been “constrained by various bottlenecks, including limited supplies of materials such as lipid nanoparticles and equipment such as bioreactor bags”.

To be sure, the raw material question is a near to medium term issue and could be still sorted. A complete waiver of all patents and know-how could still perhaps benefit the developing world in the medium to long run.

But the conclusion staring us in the face is this: There is unlikely to be a big increase in vaccine production from these moves at least in 2021. The US announcement (remember, it still has to get others such as the UK and the EU on board) is just the first step.

Stay safe and check out these reports from our independent equity research team:

Procter & Gamble Hygiene and Healthcare: Higher investment in brands, downtrading a near-term risk

What makes Mahindra CIE a buy idea despite near-term COVID challenges

Adani Ports & SEZ: No major impact on business, but valuation leaves little room for appreciation

What else are we reading?

Who benefited from the recovery and who did not?

Supply tailwinds lift sugar mill shares

Chart of the Day | PMI numbers show a squeeze in margins for companies

Digital growth can provide momentum to India’s economic turnaround

The real estate sector will need government support to revive

Chart of the Day | PMI data show employment has been shrinking for a year

Lessons in investing from John Maynard Keynes  (Republished from the FT)

Our chartists’ technical calls for the day (Please note these calls are published before the markets open on trading days): Axis Bank, HPCL and Adani Enterprises

Ravi Krishnan

Moneycontrol Pro